Surrey Heartlands

Joint Formulary & PAD

Ergocalciferol - Vitamin D deficiency and insufficiency

You are here : Home > Formulary Search > Ergocalciferol - Vitamin D deficiency and insufficiency

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines
SPC
Restrictions / Comments :
Important

On advice from specialist.

NHSE do not recommend the routine prescription of vitamins and mineral preparations, with the exceptions of patients with medically diagnosed deficiency, including those with lifelong or chronic conditions, or post surgery resulting in malabsorption (e.g.  Whipple’s procedure and some other GI surgeries), calcium and vitamin D for osteoporosis, prescription-only vitamin D analogues or malnutrition. Continuing need should be reviewed on a regular basis. Not for use for prevention of deficiency  

 

Status 2

Red
Formulations :
  • Injection
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines
R
SPC
Restrictions / Comments :
Important

Prevention or treatment of vitamin D deficiency caused by intestinal malabsorption, chronic liver disease or renal failure  (under expert supervision)

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Ergocalciferol
Indication :
Vitamin D deficiency and insufficiency
Group Name :
Keywords :
Brand Names Include :
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Vitamin D deficiency and insufficiency
Supporting Documents :
0
Traffic Light Entries :
2

Other Indications

Below are listed other indications that Ergocalciferol is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Vitamin D deficiency and insufficiency.

Committee Recommendations (1)

11 Feb 25 - Surrey Heartlands Medicines Optimisation Board (MOB)

This drug has been included on the joint formulary having been agreed by the DTC of at least one Surrey Heartlands Acute Trust.

See “Formulary Status” to identify where this drug has been agreed for use.